Five Australian Biotechs Advance Products To Late Stages
This article was originally published in PharmAsia News
Five Australian biotechs are in various advanced-stage trials for products they have developed. Avexa has entered into an agreement with Monogram Biosciences of the United States to test the Australian firm's drug candidates as it begins Phase III trials of its apricitabine drug to fight HIV. Also at the Phase II or III stage with product candidates are Bionomics, ChemGenex and Progen Pharmaceuticals. In addition, Clinuvel Pharmaceuticals gained orphan-drug designation for its CUV-1647 hormone treating sun-related cancer problems. (Click here for more
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.